title: Repeated B cell depletion in treatment of refractory systemic lupus erythematosus.
abstract: OBJECTIVE
  To report the clinical outcome and safety profile of repeated B cell depletion in seven patients with refractory systemic lupus erythematosus (SLE).
  
  
  METHODS
  Since June 2000, seven patients with refractory SLE had repeated cycles of B cell depletion (18 cycles in total, up to three cycles per patient) because of disease relapse. The clinical response (assessed by the British Isles Lupus Activity Guide (BILAG) activity index), duration of B cell depletion, and adverse events in these patients was reviewed.
  
  
  RESULTS
  Four patients (Nos 1, 2, 3, 6) had three cycles of treatment and three (Nos 4, 5, 7) had two cycles. Four of the seven patients (Nos 1, 3, 5, 6) improved. The mean global BILAG scores dropped from 15 to 6 at 5-7 months. The median duration of clinical response and B cell depletion was 13 months and 6 months, respectively. After the third cycle, 2/4 patients (Nos 1 and 2) improved. The median duration of clinical benefit was 12 months. Most patients tolerate re-treatment very well.
  
  
  CONCLUSIONS
  Re-treatment with B cell depletion of patients with severe SLE is safe and may be effective for 6-12 months on average.
authors.affiliation: Centre for Rheumatology, University College London, Arthur Stanley House, 40-50 Tottenham Street, London W1T 4NJ, UK.
authors.forename: K P
authors.initials: KP
authors.lastname: Ng
authors.forename: M J
authors.initials: MJ
authors.lastname: Leandro
authors.forename: J C
authors.initials: JC
authors.lastname: Edwards
authors.forename: M R
authors.initials: MR
authors.lastname: Ehrenstein
authors.forename: G
authors.initials: G
authors.lastname: Cambridge
authors.forename: D A
authors.initials: DA
authors.lastname: Isenberg
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001323:Autoantibodies / Q000097:blood; D001402:B-Lymphocytes / Q000276:immunology*; D003176:Complement C3 / Q000032:analysis; D003520:Cyclophosphamide / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D007136:Immunoglobulins / Q000097:blood; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D000069285:Infliximab; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy / Q000276:immunology*; D008212:Lymphocyte Depletion; D008297:Male; D008875:Middle Aged; D012008:Recurrence
chemical_list: D000911:Antibodies, Monoclonal; D001323:Autoantibodies; D003176:Complement C3; D007136:Immunoglobulins; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D000069285:Infliximab